Navigation Links
Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2008

HOPKINTON, Mass., March 31 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the report of the Company's independent registered public accounting firm regarding the Company's 2007 financial statements contained an explanatory paragraph regarding the Company's ability to continue as a going concern. NASDAQ Marketplace Rules require NASDAQ-traded companies to publicly announce if their Annual Report on Form 10-K includes an audit report containing a going concern explanatory paragraph. For further information, please refer to the Company's Annual Report on Form 10-K filed on March 31, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. CETHRIN(R), a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. The Company's lead molecular imaging product candidate is ALTROPANE(R) which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the development and commercialization of ALTROPANE and CETHRIN, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact: Sharon Correia - 508-497-2360 ext 224

Alseres Pharmaceuticals, Inc.

scorreia@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
3. Barr Pharmaceuticals, Inc. Executive Bios
4. Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
5. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
6. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
7. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
8. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
9. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
10. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
11. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... ... ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday Deals On ... 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , Delete® - ... on Botox® and Juvederm® just in time for the holiday party season. , ...
(Date:12/7/2016)... ... December 07, 2016 , ... "ProBrand Flip allows FCPX editors ... said Christina Austin - CEO of Pixel Film Studios. , ProBrand Flip includes 30 ... drop zones. Editors can select from a variety of flip book animations. In Addition, ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... “The Road ... is an everyday trial, not a one hour a week showing of hands. “The ... businessman. , Tom begins, “Perhaps you are familiar with the brass ring that you ...
(Date:12/7/2016)... ... (PRWEB) December 07, 2016 , ... ... individuals impacted by cerebral cavernous angiomas, was awarded a grant from the Julian ... engagement program. New Mexico has more people with cavernous angioma than anywhere in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to a new market research report "Clinical Decision ... Standalone), Model (Knowledge-Based), Type (Therapeutic, Diagnostic), User Interactivity (Active, Passive), Application - ... reach USD 1,519.2 Million by 2021 from USD 856.3 Million in 2016, ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... Dec. 7, 2016  Organovo Holdings, Inc. (NASDAQ: ... company focused on delivering scientific and medical breakthroughs ... Chairman and Chief Executive Officer Keith Murphy ... Wednesday, December 14, 2016 at 1:00 p.m. Eastern ... not yet familiar with the Company, an informational ...
(Date:12/7/2016)... According to the latest market ... Study on Multiplex Detection Immunoassay: North America to Dominate ... detection immunoassay market is expected to witness a CAGR of ... ...      (Logo: http://photos.prnewswire.com/prnh/20161114/438683LOGO) ...
Breaking Medicine Technology: